Table 2.
Omics studies on villous tissue of recurrent pregnancy loss patients and controls.
| Reference(s) | Cell model | Omics strategy | Gestational age | Samples size | Main findings |
|---|---|---|---|---|---|
| Qiao et al., 2016 (74) | Villus | Genomics (Whole exome sequencing) | First trimester | RPL vs NP 7 vs 2 | Compound heterozygous mutations in DYNC2H1 and ALOX15 |
| Hanna et al., 2013 (77) | Villus | Epigenomics(DNA methylation chip) | 9.5 ± 2.4 weeks | RM vs TA 33 vs 16 | ↑ CYP1A2, AXL, H19/IGF2, ICR1 |
| ↓DEFB1 (marginally) | |||||
| Du et al., 2019 (78) | Villus | Epigenomics, Transcriptomics (DNA methylation chip, RNA sequencing) | 7.826 ± 0.630 weeks | RPL vs NP 27 vs 25 | ↑ PRDM1 |
| Wang et al., 2016 (79) | Villus | Transcriptomics (lncRNA array) | 3 to 6 weeks | RPL vs NP 5 vs 5 | ↑ SCARNA9, DIO3OS, H2AZ2-DT, RP11-379F4.4 |
| ↓ PRINS, BMP1, TCL6, CTA833B7.2, RPINS | |||||
| Tang et al., 2015 (80) | Villus | Transcriptomics (miRNA microarray) | 3 to 6 weeks | RPL vs NP 15 vs 15 | ↑ MiR-149-3p, miR-4417, miR-4497 and miR-3651 |
| ↓ MiR-181d, miR-29b-1-5p, miR-24-1-5p | |||||
| Huang et al., 2018 (81) | Villus | Transcriptomics (RNA sequencing) | 9.83 ± 1.25 weeks | URPL vs NP 50 vs 50 | ↑ Lnc-ERGIC1-4, lnc-MRPS30-5, lnc-RCAN1-1, lnc-SLC4A1-1, lnc-TMEM135-8, lnc-CES1-1 |
| ↓ Lnc-FGGY-4, lncPBK-2, lnc-SOX4-1, lncAC106873.4.1-8 | |||||
| Sõber et al., 2016 (82) | Villus | Transcriptomics (RNA sequencing) | 44 to 67 days | RPL vs NP 2 vs 8 | ↑ ATF4, C3, PHLDA2, GPX4, ICAM1, SLC16A2 |
| ↓ HIST1H1B, HIST1H4A | |||||
| Tian et al., 2016 (83) | Villus | Transcriptomics (mRNA microarray) | 6 to 12 weeks | RPL vs NP 31 vs 36 | ↑ CDC20, CTSF, CCR7, NUF2 |
| ↓ IGFBP1, YY1, FGF7, CCNA2 | |||||
| Rull et al., 2012 (84) | Villus | Transcriptomics (RNA microarray) | 67.7 ± 6.6 days | RPL vs NP 13 vs 23 | ↑ S100A8, TRAIL |
| Pan et al., 2017 (85) | Villus | Proteomics (iTRAQ labeling, LC-ESI-MS/MS) | 6 to 10 weeks | RPL vs NP 4 vs 4 | ↑ AGT, APOC1, SLC1A3, GOLT1B, PRELP |
| ↓ REEP6, DNTTIP2, NOLC1, SEC11C, SRSF3 | |||||
| Gharesi et al., 2014 (86) | Villus | Proteomics (2D-PAGE, MALDI TOF/TOF technique) | 14.8 ± 2.6 weeks | RPL vs NP 5 vs 5 | ↓ CALU andENO1 |
| ↑CTSD, TUBB, TUBA1, GST, PHB, ACTB | |||||
| Wang et al., 2021 (87) | Decidua and villus | Metabolomics (Nuclear magnetic resonance) | First trimester | RPL vs NP 30 vs 30 | ↓ Succinate |
| ↑ SDHB |
DYNC2H1, dynein cytoplasmic 2 heavy chain 1; ALOX15, arachidonate 15-lipoxygenase; CYP1A2, cytochrome P450 family 1 subfamily A member 2; AXL, receptor tyrosine kinase, H19, imprinted maternally expressed transcript; IGF2, insulin like growth factor 2; DEFB1, defensin beta 1; SCARNA9, small Cajal body-specific RNA 9; DIO3OS, opposite strand upstream RNA; PRINS, psoriasis associated non-protein coding RNA induced by stress; BMP1, bone morphogenetic protein 1; TCL6, T cell leukemia/lymphoma 6; PRINS, psoriasis associated non-protein coding RNA induced by stress; ATF4, activating transcription factor 4; C3, component 3, PHLDA2, pleckstrin homology like domain family A member 2; GPX4, glutathione peroxidase 4; ICAM1, intercellular adhesion molecule 1; SLC16A2, solute carrier family 16 member 2; HIST1H, H1.5 linker histone, cluster member; HIST1H4A, H4 clustered histone 1; CDC20, cell division cycle 20; CTSF, cathepsin F; CCR7, C-C motif chemokine receptor 7; NUF2, NUF2 component of NDC80 kinetochore complex; IGFBP1, insulin like growth factor binding protein 1; FGF7, fibroblast growth factor 7; CCNA2, cyclin A2; S100A8, S100 calcium binding protein A8; APOC1, apolipoprotein C1; SLC1A3, solute carrier family 1 member 3; GOLT1B,golgi transport 1B; PRELP, proline and arginine rich end leucine rich repeat protein; REEP6, receptor accessory protein 6; DNTTIP2, deoxynucleotidyltransferase terminal interacting protein 2; NOLC1, nucleolar and coiled-body phosphoprotein 1; SEC11C, homolog C, signal peptidase complex subunit; SRSF3, serine and arginine rich splicing factor 3; CTSD, cathepsin D; TUBB, tubulin beta; TUBA1, tubulin alpha 1; GST, glutathione S-transferas; PHB, prohibitin; ACTB, actin beta; SDHB, succinate dehydrogenase B.
↑, upregulation; ↓, downregulation.